Non-muscle Invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Non-muscle Invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer [Phase 2]
TYRA-300 is being investigated in a Phase 2 trial for FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer; the stu…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
The document announces the recruitment status for a clinical evaluation of BCDx to monitor recurrence in non-muscle invasive bladder cancer.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin [Phase 2]
Phase 2 clinical trial update for Cretostimogene in non-muscle-invasive bladder cancer unresponsive to BCG, currently recruiting by Lepu Bio…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer [Phase 2]
This update summarizes a Phase 2 study of oral erdafitinib in patients with recurrent non-muscle invasive bladder cancer, including FGFR3-mu…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
This clinical trial update reports that recruitment is ongoing for a study comparing intravesical therapy and surgical options for bladder c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer [Phase 1]
Phase 1 study of PF-08052667 in non-muscle invasive bladder cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance [Phase 2]
Phase 2 clinical trial evaluating urine testing as a non-invasive surveillance method to replace cystoscopy in non-muscle-invasive bladder c…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial evaluating intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy for high-grade BCG…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC [Phase 2]
Phase 2 clinical trial evaluating intravesical gemcitabine and docetaxel for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer;…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
A clinical trial update focusing on tumor budding and T1 sub-staging in urothelial bladder cancer; recruitment is not yet started.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy [Phase 2]
Phase 2 trial evaluating TAR-200 alone or in combination with cetrelimab, and cetrelimab alone, in non-muscle invasive bladder cancer unresp…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) [Phase 3]
This clinical trial update covers a Phase 3 study evaluating TAR-200 with or without cetrelimab versus intravesical BCG in patients with hig…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) [Phase 3]
Phase 3 study comparing TAR-200 with intravesical chemotherapy in patients with recurrent high-risk non-muscle-invasive bladder cancer follo…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
A study to evaluate real-world use and outcomes of TAR-200 for non-muscle-invasive bladder cancer in the United States is currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer [Phase 1, Phase 2]
This clinical trial update describes an intravesical delivery system delivering erdafitinib for localized, non-muscle-invasive bladder cance…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer
This entry notes a clinical trial (NCT07511517) evaluating the BladMetrix urine test to monitor recurrence in non-muscle invasive bladder ca…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of Cretostimogene Grenadanorepvec in high-risk non-muscle-invasive bladder cancer.…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer [Phase 2]
This clinical trial update reports a Phase 2 study of durvalumab plus monalizumab for non-muscle invasive bladder cancer, currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy [Phase 3]
A Phase 3 clinical trial is testing adding gemcitabine to the standard Bacillus Calmette-Guérin therapy for people with recurrent non-muscle…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Bladder EpiCheck Product Development Study
This clinical trial update indicates that Nucleix Ltd.'s Bladder EpiCheck product development study is currently recruiting to evaluate its …
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) [Phase 2]
A Phase 2 study of Intismeran Autogene (V940) in combination with BCG for bladder cancer is currently recruiting, targeting non-muscle-invas…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Intravesical BCG vs GEMDOCE in NMIBC [Phase 3]
Phase 3 trial evaluating intravesical Bacillus Calmette-Guérin (BCG) versus GEMDOCE for non-muscle-invasive bladder cancer is currently acti…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of CG0070 After Transurethral Resection in Patients With IR NMIBC [Phase 1]
Clinical trial update for CG0070 in patients with non-muscle invasive bladder cancer following transurethral resection; Phase 1 study is cur…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Clinical trial update noting ongoing recruitment for a study evaluating AI-enabled blue light enhanced cystoscopy for detecting bladder canc…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer [Phase 3]
A Phase 3 trial is evaluating intravesical Nadofaragene Firadenovec versus observation in participants with intermediate-risk non-muscle inv…